Osteopetrosis Haploidentical Only Preparative Regimen ( DrugBank: - )


5 diseases
IDDisease name (Link within this page)Number of trials
19Lysosomal storage disease1
20Adrenoleukodystrophy1
125Hereditary diffuse leukoencephalopathy with spheroid1
234Peroxisomal disease (except Adrenoleukodystrophy)1
326Osteopetrosis1

19. Lysosomal storage disease


Clinical trials : 899Drugs : 684 - (DrugBank : 99) / Drug target genes : 51 - Drug target pathways : 182 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

20. Adrenoleukodystrophy


Clinical trials : 61Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 126 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

125. Hereditary diffuse leukoencephalopathy with spheroid


Clinical trial : 1Drugs : 9 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

234. Peroxisomal disease (except Adrenoleukodystrophy)


Clinical trials : 39Drugs : 35 - (DrugBank : 12) / Drug target genes : 13 - Drug target pathways : 45 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

326. Osteopetrosis


Clinical trials : 18Drugs : 43 - (DrugBank : 14) / Drug target genes : 17 - Drug target pathways : 82 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries